-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
AML, HSCs, Animal models, Diseases, platelets, MDS, red blood cells, Biological Processes, white blood cells, Technology and Procedures, Cell Lineage, Xenograft models, gene editing, Study Population, genomics, Myeloid Malignancies, hematopoiesis, flow cytometry, NGS, RNA sequencing, pathways
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Shikha Gupta, MS1*, Ana Filipa Domingues2,3,4*, Oliwia Cyran5*, George Giotopoulos, PhD2,3,6*, Sudhakaran Prabakaran, PhD5,7*, Brian J. P. Huntly, PhD, MRCP, MB, FRCPath2,3,6, Oliver M. Dovey, PhD4*, George S. Vassiliou, MD, PhD, FRCPath, MRCP2,8,9* and Cristina Pina, MD, DPhil10

1Department of Genetics, University of Cambridge, Cambridge, ENG, United Kingdom
2Department of Haematology, University of Cambridge, Cambridge, United Kingdom
3Wellcome - MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
4Wellcome Trust Sanger Institute, Cambridge, United Kingdom
5Department of Genetics, University of Cambridge, Cambridge, United Kingdom
6Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, United Kingdom
7Biology, Indian Institute of Science Education and Research, Pune, India
8Department of Haematology, University of Cambridge, Wellcome - MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
9Wellcome Trust Sanger Institute, Cambridge, ENG, United Kingdom
10College of Health, Medicine and Life Sciences - Division of Biosciences, Brunel University London, London, United Kingdom

Rachel N. Weinstein1*, Elizabeth Broadbridge1,2*, Kevin Bishop1*, Blake Carrington1*, Kai Yu, PhD1*, Abdel G. Elkahloun, PhD1*, WeiWei Wu1*, Wuhong Pei, PhD1*, Shawn M. Burgess, PhD1*, Paul P. Liu, MD, PhD1, Erica Bresciani, PhD1* and Raman Sood, PhD1*

1NHGRI, NIH, Bethesda, MD
2Johns Hopkins University, Baltimore, MD

Gordon G. L. Wong, BS1,2*, Gabriela Krivdova, BSc1,2, Olga I. Gan, PhD3*, Jessica L. McLeod3*, John E. Dick, PhD, FRS3,4 and Eric R. Lechman, PhD1

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Molecular Genetics, University of Toronto, Toronto, ON, Canada
3Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada
4Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

Akira Chiba, MD, PhD, Yosuke Masamoto, MD, PhD, Hideaki Mizuno, MD, PhD* and Mineo Kurokawa, MD, PhD

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Bruna Alves Fenerich, BSc1,2*, Jaqueline Cristina Fernandes, BSc, MSc1,2*, Cleide Lúcia Araújo Silva, MSc2*, Juan L Coelho-Silva, BSc, MSc1,2*, Antonio Bruno Alves Silva, BSc, MSc1,2*, Natasha Peixoto Fonseca, B.Sc., M.Sc.1,2*, João Agostinho Machado-Neto, PhD3* and Fabiola Traina, MD, PhD1,2

1Hematology Division of Medical Images, Hematology, and Clinical Oncology Department, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
2Center for Cell-based Therapy and Regional Hemotherapy Center, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil
3Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

*signifies non-member of ASH